Most importantly, the data establish a fresh mechanism of specific enzyme inhibition determined by the amino acid sequence of the substrate

Most importantly, the data establish a fresh mechanism of specific enzyme inhibition determined by the amino acid sequence of the substrate. The arginine methyltransferase, CARM1/PRMT4, has been shown to regulate important cellular processes such as pluripotency maintenance (16,32), differentiation (6,15,17), splicing (18), and transcriptional activation (1014), as well as tumor manifestation and progression (33,34). PF-6260933 context, inhibition of H3R17 methylation represses manifestation PF-6260933 ofp21, a p53-responsive gene, therefore implicating a possible part for H3 Arg-17 methylation in tumor suppressor function. These data set up TBBD like a novel specific inhibitor of arginine methylation and demonstrate substrate sequence-directed inhibition of enzyme activity by a small molecule and its physiological result. Keywords:Chromatin, Chromatin Histone Changes, Coactivator Transcription, Enzyme Inhibitors, Gene Manifestation, Arginine Methylation, CARM1, TBBD, Epigenetics, p53 == Intro == Arginine methylation of nonhistone proteins has been known for nearly four decades, regulating numerous cellular processes such as transcription and RNA processing, and DNA replication and restoration (1,2). However, histone arginine methylation and its part in gene rules were discovered much more recently (3). Protein arginine methyltransferases (PRMTs)3are classified into class I and class II enzymes. Class I PRMTs catalyze the formation of asymmetric dimethylarginine (involved in transcriptional activation), whereas class II enzymes are responsible for generating symmetric dimethylarginine (involved in transcriptional repression) (4). The class I enzyme CARM1 (coactivator-associated arginine methyltransferase 1, also known as PRMT4), was first identified as a p160 coactivator-interacting protein in a candida two-hybrid display, and later like a histone methyltransferase and transcriptional coactivator (5). All the PRMTs except CARM1 target a glycine arginine acknowledgement motif, whereas CARM1 recognizesXXPRXorXXRPX, whereXis any amino acid (6). CARM1 interacts with Hold1 (glucocorticoid receptor-interacting protein) and is a secondary coactivator of PF-6260933 several nuclear receptors (79). CARM1 also interacts with additional chromatin-modifying enzymes such as p300/CREB-binding protein and PRMT1 to bring about cooperative transcriptional activation of p53-responsive genes (10). CARM1 and PRMT1 relationships have also been shown to regulate gene manifestation in different contexts (11,12). CARM1 is definitely a positive regulator of bothcyclin E1(13) andNF-Bpromoter activity (14). CARM1 also participates in various other cellular processes through its ability to methylate nonhistone substrates. Recently, CARM1 has been implicated in muscle mass (15) and T-cell development (6), stem cell differentiation (16), adipocyte differentiation (17), RNA processing (18), and tumorigenesis (19). Despite such broad functional significance, the exact molecular mechanisms of the enzyme function are not understood, in part due to the unavailability of specific modulators. For example, in the case of lysine methyltransferases, only two specific inhibitors chaetocin (20) and BIX-01294 (21) are known. However, no specific inhibitor for CARM1 with appropriate characterization is known so far. There is an rigorous ongoing effort to identify specific arginine methylation inhibitors (2224). Small molecule inhibitors of protein function are powerful tools to probe the physiological functions of enzymes. Furthermore, such modulators are potential lead molecules for restorative purposes, as evidenced from the recent clinical tests of histone deacetylase inhibitors. Along with the second option, the recent discovery of specific and nontoxic small molecule modulators of histone acetyltransferases (HATs) and histone methyltransferases (HMTases) may portend a new era of epigenetic-based medicines (25). We have established a general screening procedure to identify small molecule modulators of chromatin-modifying enzymes present in plant components (from bark, stem, root, or fruit). Using this approach we discovered several small molecule modulators of HATs (25). The same components from 25 different flower sources were also screened for HMTase modulatory activity, which led to the identification of a molecule (TBBD) having specific activity toward CARM1, as reported here. This small molecule inhibitor, TBBD (ellagic acid) shows substrate sequence dependence for enzyme specific inhibition. Furthermore, the inhibitor is also active physiologically with a significant result on p53-dependent gene manifestation. == MATERIALS AND METHODS == == == == == == Protein Purifications == The details of the protein purifications are provided in thesupplementary data. == Site-directed Mutagenesis == Histone H3 point mutants A25P and P16A were acquired by site-directed mutagenesis. The histone H3 manifestation clone (Xenopus) was used as the template and mutagenesis was carried out using a Stratagene site-directed mutagenesis kit according to the manufacturer’s instructions. Rabbit Polyclonal to RIN3 Positive clones were sequenced and transformed intoEscherichia coliBL21. Manifestation and purification of the mutant protein were carried out as detailed in thesupplementary data. == HMTase Assay == HMTase assay has been performed as explained elsewhere (26), also seesupplementary data. ==.